摘要
目的:探讨加贝酯、奥曲肽和奥美拉唑联合应用预防内镜下逆行胰胆管造影(ERCP)术后胰腺炎(PEP)的作用。方法:235例ERCP术后患者随机分为治疗组(125例)和对照组(110例)。治疗组ERCP术后应用加贝酯1mg.kg-1.h-1持续静滴12h,奥曲肽0.1mg皮下注射q12h×2次,奥美拉唑40mg静注q12h×3次;对照组ERCP术后静滴生理盐水500mL。ERCP术前、术后3h、12h及24h检测血清淀粉酶并观察有无PEP的临床表现。结果:治疗组和对照组ERCP术后PEP的发生率分别为3.20%和11.82%(P<0.01),高淀粉酶血症的发生率分别为18.40%和39.09%(P<0.05)。2种并发症的发生率均有明显差异。结论:加贝酯、奥曲肽和奥美拉唑联合应用可降低ERCP术后PEP和高淀粉酶血症的发生率。
OBJECTIVE To examine prophylactic effect of gabexate, octreotide and omeprazole on post-ERCP pancreatitis. METHODS Patients scheduled for ERCP were randomized to two groups： patients in the treatment group were treated with gabexate,octreotide and omeprazole, and the control group patients were only given physiological saline. RESULTS Post-ER- CP pancreatitis occurred in 4 patients （3. 20%） of the treatment group and 13 patients （11.82%） of the control group （P〈 0. 01）, and hyperamylasemia occurred in 23 patients（ 18. 40%）of the treated group and 43 patients（39. 09% ）of the control group （P〈0. 05）. CONCLUSION Gabexate, octreotide and omeprazole can prevent post-ERCP pancreatitis and hyperamylasemia effectively.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2010年第7期582-584,共3页
Chinese Journal of Hospital Pharmacy
